Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology

CARLSBAD,Calif.,Aug. 1,2022 -- Active Motif Incorporated,a company with the vision of bringingepigenetics more deeply intoprecision medicine,announcedthatithasnon-exclusively licenseditsfoundational patents intransposition for use inCUT&Tagepigenetic assays to Diagenode S.A.,a Hologic company (NASDAQ: HOLX). Theinnovations underlying these patents allowmechanistic,translational,and clinical researchers to interrogate open chromatin with the goal of gaining an increased understanding of biological processes. Through the licensing arrangement,Diagenode gains access to Active Motif's patents,which include US9938524,EP2783001,US10689643,US11306307,EP2999784,and other related patentapplications.

Details about Active Motif's proprietary Cut&Tag-IT™technology can be found at www.activemotif.com/catalog/1318/cut-tag-it-kit

About Active Motif

Active Motif,Inc. is dedicated to developing,manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include scientists from academic and government institutions; biotechnology and pharmaceutical companies. Active Motif operates globally through its corporate headquarters in Carlsbad,California and offices in Shanghai China,Tokyo Japan and Waterloo Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.

Media Contact: Fritz Eibel,Active Motif Incorporated,Feibel@activemotif.com